Unique Wealth Strategies LLC Makes New $1.07 Million Investment in Pfizer Inc. (NYSE:PFE)

Unique Wealth Strategies LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 37,134 shares of the biopharmaceutical company’s stock, valued at approximately $1,069,000.

Several other large investors have also recently added to or reduced their stakes in PFE. Intact Investment Management Inc. lifted its holdings in shares of Pfizer by 30.9% during the 4th quarter. Intact Investment Management Inc. now owns 438,800 shares of the biopharmaceutical company’s stock worth $12,633,000 after acquiring an additional 103,600 shares during the period. Addison Advisors LLC boosted its holdings in shares of Pfizer by 11.6% in the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 970 shares during the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $962,000. Headlands Technologies LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $1,184,000. Finally, Citizens Financial Group Inc. RI raised its position in shares of Pfizer by 40.7% in the 4th quarter. Citizens Financial Group Inc. RI now owns 145,969 shares of the biopharmaceutical company’s stock worth $4,202,000 after buying an additional 42,202 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Up 0.6 %

Shares of Pfizer stock traded up $0.14 during trading hours on Friday, hitting $25.40. 46,526,457 shares of the company’s stock traded hands, compared to its average volume of 34,120,812. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock has a 50 day simple moving average of $26.96 and a 200-day simple moving average of $28.42. The company has a market cap of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.14 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.